Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra 16:39:34 19/07/2024 BST 5-day change 1st Jan Change
26.26 EUR -2.63% Intraday chart for Bayer AG -2.51% -21.91%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Global markets live: Adidas, TSMC, Vale, HSBC, J&J... Our Logo
Bayer: successful trial in prostate cancer CF
BAYER AG : JP Morgan remains Neutral ZD
Bayer: new positive data for Nubeqa CF
Bayer with trial success in prostate cancer - Analyst: As expected DP
BAYER AG : Goldman Sachs sticks Neutral ZD
Bayer's Prostate Cancer Combo Extends Progression-Free Survival in Late-stage Trial MT
Bayer's Nubeqa Meets Key Goal in Late-Stage Prostate Cancer Trial DJ
Bayer eyes wider Nubeqa use on new prostate cancer trial data RE
Bayer seeks approval extension for cancer drug Nubeqa following positive data RE
Bayer with trial success in prostate cancer - Larger patient group responsive DP
Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint CI
ORIC Pharmaceuticals, Inc. Enters into Clinical Trial Collaboration and Supply Agreements with Bayer and Janssen Research & Development, LLC CI
BAYER AG : UBS sticks Neutral ZD
European companies cut jobs as economy sputters RE
European Midday Briefing : Stocks Extend Rally as U.S. Rate Cut Hopes Deepen DJ
BAYER AG : Jefferies gives a Neutral rating ZD
Cooling Inflation in Germany, US Boosts DAX Index MT
Bayer: FDA Fast Track designation for Parkinson's treatment CF
Bayer's Gene Therapy for Parkinson's Gets US Fast Track, UK Innovation Passport Designations MT
Fast-track status for gene therapy boosts Bayer DP
BASF announces planned closure of two weed killer sites in Germany RE
BAYER AG : JP Morgan reaffirms its Neutral rating ZD
European companies cut jobs as economy sputters RE
BAYER AG : Gets a Neutral rating from Deutsche Bank ZD
Chart Bayer AG
More charts
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
26.26 EUR
Average target price
35.91 EUR
Spread / Average Target
+36.74%
Consensus
  1. Stock Market
  2. Equities
  3. BAYN Stock
  4. News Bayer AG
  5. Bayer's Crop Science Business Developing AI to Kill Weeds